Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Summit Therapeutics plc (SUMM) Ordinary Shares 1p

Sell:20.00p Buy:23.00p 0 Change: No change
Market closed Prices as at close on 13 December 2019 Prices delayed by at least 15 minutes | Switch to live prices |
Delisting

Summit Therapeutics plc Ordinary Shares 1p

Type:
Delisting
Shareholder action required:
Yes
Status:
Client deadline
Details (last updated 13 Dec 2019)

What is happening?

 

The Board of Summit Therapeutics plc has announced proposals to cancel the Company’s ordinary shares from trading on AIM (Alternative Investment Market). It is expected that the Company’s shares will be delisted with effect from 7am on Monday 24 February 2020.

 

If the Delisting is approved at the shareholder Meeting Summit Therapeutics will be offering shareholders the opportunity to convert their ordinary shares into American depositary receipts (ADRs). ADRs are a form of stock traded in the US that represent a number of Shares in a foreign Company. If approved we will write to you after the Shareholder Meeting to inform you of the terms of the conversion.

 

Why is this happening?


“The AIM Delisting reflects the increasing focus of the Company’s business operations on the United States.” (Source: Shareholder announcement, 6 December 2019)

 

What action do I need to take?

 

For the delisting to become effective, it must be approved at a General Meeting to be held on Monday 23 December 2019. Under AIM Rules, such a withdrawal resolution requires the consent of not less than 75% of votes cast by shareholders voting on the resolutions at the General Meeting.

 

If you would like to submit a vote for or against the resolution to delist the shares, please provide us with your voting instruction by noon on Wednesday 18 December 2019.

 

If you wish to sell your holding before the proposed listing cancellation you must do so before the expected last day of trading 4.30pm on Friday 21 February 2020. The trade will be placed in accordance with our terms and conditions and subject to the standard Stockbrokers commission rates. To sell these Shares please phone us on 0117 980 9800 or you can place a trade online.

 

Please note that if the cash consideration of a sale does not exceed the commission payable then the sale will not be executed. Please note that although Hargreaves Lansdown will endeavor to sell your Shares it may not be possible to sell all, or even any, of your Shares if a market for the Shares no longer exists. If you dispose of your holding before shareholder approval has been granted you do so at your own risk. 

 

If you wish to maintain your holding you need take no action. You should note that following the cancellation you may have difficulty selling this investment at a reasonable price and, in some circumstances, it may be impossible to sell it at any price.

 

Full details of this event will be sent to Qualifying Hargreaves Lansdown clients by either post or secure message. Please note that any instruction you give must be based on the full details provided in the letter and not on the summary information outlined above.

×
Sell:20.00p
Buy:23.00p
Change: No change
Market closed Prices as at close on 13 December 2019 Prices delayed by at least 15 minutes | Switch to live prices |
Delisting

Summit Therapeutics plc Ordinary Shares 1p

Type:
Delisting
Shareholder action required:
Yes
Status:
Client deadline
Details (last updated 13 Dec 2019)

What is happening?

 

The Board of Summit Therapeutics plc has announced proposals to cancel the Company’s ordinary shares from trading on AIM (Alternative Investment Market). It is expected that the Company’s shares will be delisted with effect from 7am on Monday 24 February 2020.

 

If the Delisting is approved at the shareholder Meeting Summit Therapeutics will be offering shareholders the opportunity to convert their ordinary shares into American depositary receipts (ADRs). ADRs are a form of stock traded in the US that represent a number of Shares in a foreign Company. If approved we will write to you after the Shareholder Meeting to inform you of the terms of the conversion.

 

Why is this happening?


“The AIM Delisting reflects the increasing focus of the Company’s business operations on the United States.” (Source: Shareholder announcement, 6 December 2019)

 

What action do I need to take?

 

For the delisting to become effective, it must be approved at a General Meeting to be held on Monday 23 December 2019. Under AIM Rules, such a withdrawal resolution requires the consent of not less than 75% of votes cast by shareholders voting on the resolutions at the General Meeting.

 

If you would like to submit a vote for or against the resolution to delist the shares, please provide us with your voting instruction by noon on Wednesday 18 December 2019.

 

If you wish to sell your holding before the proposed listing cancellation you must do so before the expected last day of trading 4.30pm on Friday 21 February 2020. The trade will be placed in accordance with our terms and conditions and subject to the standard Stockbrokers commission rates. To sell these Shares please phone us on 0117 980 9800 or you can place a trade online.

 

Please note that if the cash consideration of a sale does not exceed the commission payable then the sale will not be executed. Please note that although Hargreaves Lansdown will endeavor to sell your Shares it may not be possible to sell all, or even any, of your Shares if a market for the Shares no longer exists. If you dispose of your holding before shareholder approval has been granted you do so at your own risk. 

 

If you wish to maintain your holding you need take no action. You should note that following the cancellation you may have difficulty selling this investment at a reasonable price and, in some circumstances, it may be impossible to sell it at any price.

 

Full details of this event will be sent to Qualifying Hargreaves Lansdown clients by either post or secure message. Please note that any instruction you give must be based on the full details provided in the letter and not on the summary information outlined above.

×
Sell:20.00p
Buy:23.00p
Change: No change
Market closed Prices as at close on 13 December 2019 Prices delayed by at least 15 minutes | Switch to live prices |
Delisting

Summit Therapeutics plc Ordinary Shares 1p

Type:
Delisting
Shareholder action required:
Yes
Status:
Client deadline
Details (last updated 13 Dec 2019)

What is happening?

 

The Board of Summit Therapeutics plc has announced proposals to cancel the Company’s ordinary shares from trading on AIM (Alternative Investment Market). It is expected that the Company’s shares will be delisted with effect from 7am on Monday 24 February 2020.

 

If the Delisting is approved at the shareholder Meeting Summit Therapeutics will be offering shareholders the opportunity to convert their ordinary shares into American depositary receipts (ADRs). ADRs are a form of stock traded in the US that represent a number of Shares in a foreign Company. If approved we will write to you after the Shareholder Meeting to inform you of the terms of the conversion.

 

Why is this happening?


“The AIM Delisting reflects the increasing focus of the Company’s business operations on the United States.” (Source: Shareholder announcement, 6 December 2019)

 

What action do I need to take?

 

For the delisting to become effective, it must be approved at a General Meeting to be held on Monday 23 December 2019. Under AIM Rules, such a withdrawal resolution requires the consent of not less than 75% of votes cast by shareholders voting on the resolutions at the General Meeting.

 

If you would like to submit a vote for or against the resolution to delist the shares, please provide us with your voting instruction by noon on Wednesday 18 December 2019.

 

If you wish to sell your holding before the proposed listing cancellation you must do so before the expected last day of trading 4.30pm on Friday 21 February 2020. The trade will be placed in accordance with our terms and conditions and subject to the standard Stockbrokers commission rates. To sell these Shares please phone us on 0117 980 9800 or you can place a trade online.

 

Please note that if the cash consideration of a sale does not exceed the commission payable then the sale will not be executed. Please note that although Hargreaves Lansdown will endeavor to sell your Shares it may not be possible to sell all, or even any, of your Shares if a market for the Shares no longer exists. If you dispose of your holding before shareholder approval has been granted you do so at your own risk. 

 

If you wish to maintain your holding you need take no action. You should note that following the cancellation you may have difficulty selling this investment at a reasonable price and, in some circumstances, it may be impossible to sell it at any price.

 

Full details of this event will be sent to Qualifying Hargreaves Lansdown clients by either post or secure message. Please note that any instruction you give must be based on the full details provided in the letter and not on the summary information outlined above.

×
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.
Open:
21.50p
Trade high:
22.70p
Year high:
34.00p
Market capitalisation
Market cap.
:
£35.29 million
Previous close:
22.00p
Trade low:
21.00p
Year low:
18.00p
P/E ratio:
2.44
Previous:
0.00p (0.00%)
Previous:
0.00p
Volume:
173,140
Dividend yield:
n/a
EMS:
3,000
Data delayed by at least 15 minutes.

Performance

Not available for this stock.

Fundamental data

Year ending: 31/01/2019 31/01/2018
Revenue (£m) 43.01 25.42
Profit before tax (£m) 5.03 (10.89)
Adjusted EPS (p): 9.00 (11.00)
P/E ratio 2.40 n/a
PEG n/a n/a
EPS growth (%) n/a n/a

Values are quoted in the stock's local currency: British pound

All fundamental data

Dividend information for this stock is not available.

Dividend information for this stock is not available.

Ready to invest?

To buy shares in , you'll need to have an account. Try our handy filter to explore the different options.

Compare accounts

Ready to take your first step?

To invest in , you'll need to open an account.
Try our handy filter to find which one suits you best.

Compare accounts

Important Documents

There are no documents available for this stock.

Broker forecasts

Broker recommendations for this stock are not available.

Time / date Time Buy / sell Type Volume Price Value
×

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled ‘N/A’.

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Prices provided by NBTrader. Charts provided by Factset. 'Broker forecast' and 'Recent trades' provided by MoneyAM. News and fundamental data provided by Digital Look.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.